Novo Nordisk (NVO) is partnering with Hims & Hers (HIMS), LifeMD (LFMD), Ro, and other telehealth companies to offer Wegovy, its popular weight loss drug, to more U.S. patients, Bloomberg’s Madison Muller reports. The telehealth companies will sell a month’s supply of Wegovy through NovoCare, Novo Nordisk’s direct-to-consumer pharmacy platform, starting at $499, a discount of nearly 63% from the drug’s U.S. list price, before subscription fees, according to the report. Rival Eli Lilly (LLY) previously teamed up with Ro and other telehealth firms to distribute lower cost vials of Zepbound, its obesity medication.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk, Hims & Hers announce obesity care collaboration
- Eli Lilly Stock (LLY) Is Double Downgraded Ahead of Earnings
- Novo Nordisk price target lowered to $102 from $160 at HSBC
- Novo Nordisk downgraded to Sell from Buy at DBS Bank
- Novo Nordisk downgraded to Market Perform from Outperform at BMO Capital
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue